Inotuzumab Ozogamicin - PF-05208773
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03127605 |
Expanded Access Status :
Approved for marketing
First Posted : April 25, 2017
Last Update Posted : May 18, 2020
|
Sponsor:
Pfizer
Information provided by (Responsible Party):
Pfizer
- Study Details
- Tabular View
- Disclaimer
- How to Read a Study Record
Brief Summary:
Inotuzumab Ozogamicin Expanded Access Program
Intervention/treatment |
---|
Drug: Inotuzumab Ozogamicin |
Study Type : | Expanded Access |
Expanded Access Type : | Individual Patients |
Resource links provided by the National Library of Medicine

Drug Information available for:
Inotuzumab ozogamicin
Intervention Details:
- Drug: Inotuzumab Ozogamicin
Other Name: PF-05208773
Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | Child, Adult, Older Adult |
Criteria
Inclusion Criteria:
-
Exclusion Criteria:
-
No Contacts or Locations Provided
Responsible Party: | Pfizer |
ClinicalTrials.gov Identifier: | NCT03127605 |
Other Study ID Numbers: |
B193 |
First Posted: | April 25, 2017 Key Record Dates |
Last Update Posted: | May 18, 2020 |
Last Verified: | May 2020 |
Additional relevant MeSH terms:
Inotuzumab Ozogamicin Antineoplastic Agents |